Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif., Dec. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), ...
PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif., Aug ...
New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology "The new products we have planned for 2024 will take 10x to ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
• Troy Randall – Med – Clinical Immunology and Rheumatology - The epigenetic modifier Kmt2a regulates humoral responses to influenza by orchestrating B cell function in the pre-inducible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback